Scarica l'app Stockscreener
812.27
4.60%
35.73
Pre-mercato:
805.25
-7.02
-0.86%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$776.54
Aprire:
$786.18
Volume 24 ore:
1.26M
Relative Volume:
1.27
Capitalizzazione di mercato:
$85.37B
Reddito:
$14.25B
Utile/perdita netta:
$4.58B
Rapporto P/E:
19.45
EPS:
41.7701
Flusso di cassa netto:
$3.88B
1 W Prestazione:
+5.23%
1M Prestazione:
+13.07%
6M Prestazione:
+50.95%
1 anno Prestazione:
+11.22%
Intervallo 1D:
$780.10
$814.10
Intervallo di 1 settimana:
$753.20
$814.10
Portata 52W:
$476.49
$814.10
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Diabetic Retinopathy Market to Witness Remarkable Growth With - openPR.com
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - MSN
Analyst Upgrades And Short-Interest Drop Might Change The Case For Investing In Regeneron (REGN) - Yahoo Finance
Regeneron Just Moved From Underperform To BuyHere's Why - Benzinga
This Lowe's Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday (CORRECTED) - Benzinga
Regeneron Stock Lagged Behind the S&P 500 Last Year. Why This Firm Moved Off the Sidelines. - Barron's
Regeneron upgraded at BoA on Eylea HD, Dupixent, and pipeline - Seeking Alpha
Regeneron Science Talent Search: 33 Long Island students named semifinalists - Newsday
Regeneron Pharmaceuticals upgraded by Bank of America on improving fundamentals, 2026 catalysts - Proactive financial news
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Finviz
Regeneron Pharma gains as BofA upgrades rating - TradingView — Track All Markets
Why Regeneron (REGN) Stock Is Trading Up Today - Finviz
Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 12-Month High After Analyst Upgrade - MarketBeat
Regeneron Pharmaceuticals stock hits 52-week high at $795.88 By Investing.com - Investing.com India
Regeneron Pharmaceuticals stock hits 52-week high at $795.88 - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Bank of America - MarketBeat
Analyst Upgrade: Regeneron Pharmaceuticals (REGN) Rating Boosted to Buy | REGN Stock News - GuruFocus
21 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know - Benzinga
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
Merit Financial Group LLC Has $1.05 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diabetic Macular Edema Market to hit US$ 7.44 Billion by 2033 | Top - openPR.com
Will Regeneron Pharmaceuticals Inc. stock maintain dividend yield2026 world cup usa national team round of 32 key players low block defense group prediction preview - Улправда
Regeneron Upgraded From Underperform to Buy – Here’s the Reason - Bitget
The Truth About Regeneron Pharm: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Looking at the Latest Short Interest Trends for Regeneron Pharmaceuticals Inc - Bitget
Peering Into Regeneron Pharmaceuticals Inc's Recent Short Interest - Benzinga
How Dupixent’s New Pediatric Asthma Nod in Japan Will Impact Regeneron Pharmaceuticals (REGN) Investors - simplywall.st
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Regeneron Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth - TradingView — Track All Markets
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson - The Globe and Mail
Regeneron Pharmaceuticals Inc RGO Stock Analysis and ForecastStock Screening Results & Big Gains Low Budget - earlytimes.in
Intellia Stock Declines Around 55% in 3 Months: Here's Why - TradingView — Track All Markets
Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026 - The Globe and Mail
Regeneron Pharmaceuticals Inc Stock Analysis and ForecastAnalyst Downgrades & Small Budget Capital Gains - earlytimes.in
Allspring Global Investments Holdings LLC Sells 6,253 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Navigating the Biotech Giant’s Growth Potential and Analyst Ratings - DirectorsTalk Interviews
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Momentum - simplywall.st
Regeneron (REGN) Valuation Check After Japan Clears Dupixent for Pediatric Severe Asthma Expansion - Yahoo Finance
Regeneron Shares Maintain Momentum as Key Catalysts Align - AD HOC NEWS
Financiere des Professionnels Fonds d investissement inc. Acquires Shares of 3,171 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Who Owns Regeneron Pharmaceuticals? Top Shareholders and Recent Insider Trades - TIKR.com
Brookwood Investment Group LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results - MSN
Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week - MSN
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026 - The Manila Times
Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026 - Quiver Quantitative
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host ... - Caledonian Record
In Case You Missed It: Trial Updates, FDA Approvals & Rejections - Citeline News & Insights
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Finviz
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MSN
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):